Navigation Links
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
Date:5/20/2008

eding and stool frequency as a modified UC-DAI sub-score of 0.

Overall, a total of 341 patients with active, mild to moderate UC were analyzed as part of this post hoc analysis of an 8-week study. Patients in the Kamm study received LIALDA 2.4g/day once daily (n=84), 4.8g/day once daily (n=85), Asacol 2.4g/day three times daily (n=86); or placebo (n=86).

The post hoc analysis found that regardless of the definition used for remission, treatment with LIALDA 2.4g/day, or 4.8g/day, or Asacol 2.4g/day resulted in similar median times to symptom resolution that were shorter than placebo. The Kamm study was not designed to compare LIALDA to Asacol. Asacol was included in the study as a reference arm only.

-- Symptom resolution of rectal bleeding at the first day and first of

three days, respectively:

-- LIALDA 2.4g/day: 9 days and 18 days

-- LIALDA 4.8g/day: 9 days and 17 days

-- Placebo: 14 days and 35 days

-- Normalization of stool frequency at the first day and first of three

days, respectively:

-- LIALDA 2.4g/day: 20 days and 33 days

-- LIALDA 4.8g/day: 23 days and 38 days

-- Placebo: 38 days and 53 days

-- Resolution of both rectal bleeding and normalization of stool

frequency at the first day and first of three days, respectively:

-- LIALDA 2.4g/day: 27 days and 37 days

-- LIALDA 4.8g/day: 29 days and 45 days

-- Placebo: 44 days and 56 days

Important Safety Information for LIALDA

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond 8 weeks have not been established.

LIALDA is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of LIALDA. Caution should be exercised
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader in ... partnership with RCA Medical, a subsidiary of Ascendis Health ... Each year, hundreds of millions of patients ... as organisms are transmitted from patient to patient via ...
(Date:1/23/2015)... 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) ... "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with the ... provides an update for shareholders detailing why a "YES" vote ... Dear Shareholders, As we reflect upon the ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Germany, Jan. 18, 2011 Amgen Inc. (Nasdaq: ... have signed an agreement under which Boehringer Ingelheim will ... Amgen,s Fremont California development and manufacturing facility. ... directors of each company and is expected to close ...
... The Lanier Law Firm and attorneys from around ... status conference involving hip implant cases in In re: DePuy ... 2197 ) . U.S. District Judge David A. ... Ohio is holding the initial coordination hearing in West Palm Beach ...
Cached Medicine Technology:Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 2Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 3Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 4Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 5The Lanier Law Firm Readies for First Hearing in Nationwide Hip Implant Litigation 2
(Date:1/22/2015)... Bradley, Illinois (PRWEB) January 22, 2015 Deer ... -- will host a Valentine’s Day Happy Hour from 3 p.m. ... located at 12500 Regency Parkway in Huntley, Illinois, serves adults with ... Happy Hour event will include Valentine's Day treats, games and sweetheart-themed ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... a famous wedding dress company offering many trendy designs. Today, ... Twitter, and Pinterest. The fans will have an opportunity to ... week. , Moreover, the company has extended its 2015 New ... for more information. , Angelweddingdress is a famous ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Kmart aligns with the American Diabetes Association to raise ... The American,Diabetes Association (ADA) today announced that Kmart ... for the diabetes community by,becoming a National Strategic Partner ... least $1 million to support ADA,s mission to,prevent and ...
... Philadelphia, PA, October 1, 2007 Two studies in ... in refining recommendations for the use of colonoscopy to ... patients with large polyps or adenomaspre-cancerous growths that may ... frequent follow-up, while those with only a few small ...
... popular prostate cancer treatment called androgen deprivation therapy may ... makes them more likely to spread throughout the body, ... , Although the finding could eventually lead to changes ... the Johns Hopkins researchers caution that their discovery is ...
... chance of trouble down the road, study says , , MONDAY, Oct. ... of TV, turn it off now and save yourself a lot ... that suggests that the negative effects of lots of early TV ... age of 6. , The study doesn,t confirm that television is ...
... Ill. Women with severe premenstrual syndrome (PMS) perceive ... their symptoms in the late luteal (premenstrual) phase, despite ... with premenstrual symptoms, according to a study published in ... The study, authored by Fiona C. Baker, PhD, of ...
... for two or more hours in early childhood can lead ... study of children 2.5 to 5.5 years of age conducted ... Health. The Hopkins researchers found that the impact of TV ... the age at which the viewing occurred. More importantly, heavy ...
Cached Medicine News:Health News:Kmart Steps Out to Fight Diabetes 2Health News:Kmart Steps Out to Fight Diabetes 3Health News:Studies lend insights into colorectal cancer screening 2Health News:Studies lend insights into colorectal cancer screening 3Health News:Standard treatment for prostate cancer may encourage spread of disease 2Health News:Kids' TV Viewing Tied to Behavioral Problems 2Health News:Kids' TV Viewing Tied to Behavioral Problems 3Health News:Women with severe PMS perceive their sleep quality to be poor 2Health News:Childhood TV viewing a risk for behavior problems 2
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dl (27.8 mmol/l). Single vial, dry powder reagent....
Medicine Products: